Aptose Biosciences Stock

Aptose Biosciences ROCE 2024

Aptose Biosciences ROCE

18.05

Ticker

APS.TO

ISIN

CA03835T2002

WKN

A12C5N

In 2024, Aptose Biosciences's return on capital employed (ROCE) was 18.05, a -1,698.83% increase from the -1.13 ROCE in the previous year.

Aptose Biosciences Aktienanalyse

What does Aptose Biosciences do?

The company Aptose Biosciences was founded in 1986 and is based in Toronto, Canada. It specializes in the discovery and development of drugs for the treatment of cancer and other serious diseases. History: Aptose Biosciences was originally known as Lorus Therapeutics, specializing in the development of antibodies and peptides. However, in 2007, the company changed its name to Aptose Biosciences and focused on cancer drugs. In 2011, Aptose obtained the license for CG'806, a promising cancer therapy that was later introduced into clinical development in 2017. Business model: Aptose Biosciences' business model is based on the discovery and development of drugs for the treatment of cancer and other serious diseases. The company works closely with leading scientists and researchers to identify and develop new and innovative therapies that have the potential to improve patients' lives. Aptose Biosciences also collaborates with pharmaceutical companies worldwide to advance the development and commercialization of its products. Divisions: Aptose Biosciences focuses on two main areas: the discovery and development of cancer therapies and the discovery of biomarkers that can be used in the diagnosis and treatment of cancer. The cancer therapy division of Aptose focuses on the development of drugs that can target the causes of cancer. The company utilizes innovative technologies to identify and develop new and promising drug candidates that have the potential to improve the lives of patients with various types of cancer. The biomarker division of Aptose focuses on the discovery of biomarkers that can be useful in the diagnosis and treatment of cancer. The company collaborates closely with other companies and research institutions to identify and validate new biomarkers that can contribute to the improvement of cancer diagnosis and treatment. Products: Aptose Biosciences currently offers several cancer drugs that are in different stages of clinical development. The most promising product of Aptose Biosciences is CG'806, which is currently in phase 1 clinical development. CG'806 is a first-in-class cancer drug that has the potential to combat multiple types of cancer. Other products of Aptose Biosciences include APTO-253, which is used for the treatment of AML (acute myeloid leukemia), and APTO-267, which is used for the treatment of CLL (chronic lymphocytic leukemia). Additionally, Aptose Biosciences is working on the development of other cancer therapies that are in various stages of development. Conclusion: Aptose Biosciences is a leading biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other serious diseases. The company has several promising cancer therapies in different stages of clinical development, as well as a promising biomarker division specializing in cancer diagnosis and treatment. With a strong focus on innovation and collaboration, Aptose Biosciences remains an important player in cancer research and therapy. Aptose Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Aptose Biosciences's Return on Capital Employed (ROCE)

Aptose Biosciences's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Aptose Biosciences's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Aptose Biosciences's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Aptose Biosciences’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Aptose Biosciences stock

What is the ROCE (Return on Capital Employed) of Aptose Biosciences this year?

The ROCE of Aptose Biosciences is 18.05 undefined this year.

How has the ROCE (Return on Capital Employed) of Aptose Biosciences developed compared to the previous year?

The ROCE of Aptose Biosciences has increased by -1,698.83% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Aptose Biosciences?

A high Return on Capital Employed (ROCE) indicates that Aptose Biosciences has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Aptose Biosciences?

A low ROCE (Return on Capital Employed) can indicate that Aptose Biosciences has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Aptose Biosciences impact the company?

An increase in the ROCE of Aptose Biosciences can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Aptose Biosciences affect the company?

A decrease in ROCE of Aptose Biosciences can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Aptose Biosciences?

Some factors that can affect Aptose Biosciences's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Aptose Biosciences so important for investors?

The ROCE of Aptose Biosciences is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Aptose Biosciences take to improve the ROCE?

To improve the ROCE, Aptose Biosciences can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Aptose Biosciences pay?

Over the past 12 months, Aptose Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aptose Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Aptose Biosciences?

The current dividend yield of Aptose Biosciences is .

When does Aptose Biosciences pay dividends?

Aptose Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aptose Biosciences?

Aptose Biosciences paid dividends every year for the past 0 years.

What is the dividend of Aptose Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aptose Biosciences located?

Aptose Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aptose Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aptose Biosciences from 11/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did Aptose Biosciences pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of Aptose Biosciences in the year 2023?

In the year 2023, Aptose Biosciences distributed 0 USD as dividends.

In which currency does Aptose Biosciences pay out the dividend?

The dividends of Aptose Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Aptose Biosciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Aptose Biosciences

Our stock analysis for Aptose Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aptose Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.